Affordable Access

deepdyve-link
Publisher Website

Design and synthesis of a novel glycosphingolipid derived from polyhydroxy 2-pyrrolidinone and phytoceramide appended by a 1,​2,​3-​triazole linker.

Authors
  • Gorantla, Jaggaiah N1
  • Faseela, Akkarammal2
  • Lankalapalli, Ravi S3
  • 1 Academy of Scientific and Innovative Research (AcSIR), New Delhi 110001, India; Chemical Sciences and Technology Division, CSIR-National Institute for Interdisciplinary Science and Technology, Thiruvananthapuram 695019, Kerala, India. , (India)
  • 2 Chemical Sciences and Technology Division, CSIR-National Institute for Interdisciplinary Science and Technology, Thiruvananthapuram 695019, Kerala, India. , (India)
  • 3 Academy of Scientific and Innovative Research (AcSIR), New Delhi 110001, India; Chemical Sciences and Technology Division, CSIR-National Institute for Interdisciplinary Science and Technology, Thiruvananthapuram 695019, Kerala, India. Electronic address: [email protected] , (India)
Type
Published Article
Journal
Chemistry and physics of lipids
Publication Date
Jan 01, 2016
Volume
194
Pages
158–164
Identifiers
DOI: 10.1016/j.chemphyslip.2015.08.002
PMID: 26254857
Source
Medline
Keywords
License
Unknown

Abstract

Synthetic analogs of glycosphingolipids (GSLs) have been demonstrated as potential therapeutic interventions in certain patho-physiological conditions. This article reviews reports of various bioactive synthetic GSLs, emanated from the Bittman laboratory. KRN7000, a synthetic GSL which is a α-galactosylceramide (α-GalCer) is a potent immunomodulatory agent. Bittman et al. reported several modifications of C-glycosides of KRN7000 with an eye towards achieving selective cytokine response during iNKT cell activation. However, GSLs with azasugar variants were not explored which inspired us to derive a polyhydroxy 2-pyrrolidinone azasugar from d-galactose and append to the phytoceramide via a 1,2,3-triazole linker to afford GSL analog 12. This novel GSL analog 12 may be used to explore the immunomodulatory activity, and other biological activities against targets involving iminosugar or azasugar based therapeutics.

Report this publication

Statistics

Seen <100 times